Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Khadavi

Sports Medicine Overland Park, KS Medical Doctor

NPI 1003050204 CMS profile 272197

10777 Nall Ave Ste 300, Overland Park, KS 66211

Open in the dashboard

General payments

$278,039

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Khadavi of Overland Park, KS is reported in the CMS Open Payments database as having received $278,039 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $59,727 24
2024 General $100,951 69
2023 General $10,225 14
2021 General $25,963 23
2020 General $15,974 18
2019 General $65,199 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Khadavi
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Michael Khadavi were reported at $59,727. Among 250 Sports Medicine profiles paid that year, the median was $119 and the middle half received between $39 and $268.

Show as a table
Year Michael Khadavi Sports Medicine median Middle half National median
2019 $65,199 $125 $45–$345 $163
2020 $15,974 $96 $33–$311 $114
2021 $25,963 $113 $34–$344 $132
2022 $0 $100 $35–$293 $149
2023 $10,225 $100 $42–$324 $160
2024 $100,951 $139 $45–$319 $164
2025 $59,727 $119 $39–$268 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $276,957 180 payments
  2. Titan Surgical Group, LLC $227 6 payments
  3. Ge Healthcare $184 5 payments
  4. Tenex Health Inc. $174 1 payment
  5. Curonix LLC $98 1 payment
  6. Horizon Therapeutics plc $93 5 payments
  7. Merz North America, Inc. $75 1 payment
  8. Flexion Therapeutics, Inc. $37 2 payments
  9. Trice Medical, Inc. $34 1 payment
  10. Zimmer Biomet Holdings, Inc. $29 2 payments
  11. Other $131 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $215,777 48 payments
  2. Consulting Fee $46,188 13 payments
  3. Travel and Lodging $12,911 62 payments
  4. Food and Beverage $3,164 89 payments
Products named General payments · program years 2019–2025
  1. Arthrex $16,380 12 payments
  2. BIOLOGICS CONSUMABLES AUTOLOGOUS BLOOD PRODUCTS AUTOLOGOUS THROMBIN $118 1 payment
  3. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $98 1 payment
  4. PENNSAID $77 4 payments
  5. Xeomin $75 1 payment
  6. Zilretta $37 2 payments
  7. EBI Bone Healing System $29 2 payments
  8. CMF OL1000 $22 1 payment
  9. MYOBLOC $20 1 payment
  10. EUFLEXXA $18 1 payment
  11. Other $126 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

608

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,957

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

8.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 206 $2,304
Pregabalin Generic 17 $544
Celecoxib Generic 13 $528
Tramadol Hcl Generic 87 $458
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 49 $319
Cyclobenzaprine Hcl Generic 38 $287
Meloxicam Generic 59 $178
Ondansetron Hcl Generic 23 $118
Lorazepam Generic 92 $93
Tizanidine Hcl Generic 12 $71

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$141,739

Of which drugs: $29,990

Medicare patients

365

Average age 74

Services billed

7,119

232 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Ischemic heart disease 27%
Osteoporosis 23%
Depression 21%
Chronic kidney disease 18%
Diabetes 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 30 47 $25,068
Injection, methylprednisolone acetate, 1 mg J1010 Office 80 4,916 $487
Injection, methylprednisolone acetate, 40 mg J1030 Office 37 59 $267

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record